Major drugmaker loses $27 billion in market value after failed trial. Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
A apuração publicada por www.marketwatch.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
- Ponto de atenção: major.
- Ponto de atenção: drugmaker.
- Ponto de atenção: loses.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Carreira.